Nanobiotix S.A. Logo

Nanobiotix S.A.

Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.

NBTX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. The company's lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed for direct injection into solid tumors. When activated by radiotherapy, NBTXR3 locally amplifies the radiation dose within the tumor, aiming to enhance cancer cell destruction without increasing exposure to surrounding healthy tissues. This process is also intended to prime the immune system to attack metastatic cancer cells. Through a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, Nanobiotix is co-developing NBTXR3, initially focusing on cancers of the head, neck, and lungs for patient populations with limited treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.